pros and cons of glp-1 drugs Do The Benefits OutWeigh the Negatives? GLP-1 RA drugs: the basics,
Description
A lower, fixed dose for those who want a gentle, mindful, cosmetic approach rather than full dose weight loss
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
In 2024, we also saw unprecedented willingness by large numbers of patients to pay out of pocket, even in European markets, as public coverage of AOMs is still limited, at best, and more often non-existent
CMS GLP-1 Bridge Program: Medicare Part D coverage for weight-loss GLP-1 drugs starting July 1, 2026, including eligibility, covered medications, prior authorization, and copay rules.
